A Phase I Safety and Pharmacokinetic Study of Everolimus, an Oral mTOR Inhibitor, in Subjects With Impaired Hepatic Function

Authors
Peveling-Oberhag J. 1 , Zeuzem S. 1 , Yong W.P. 2 , Kunz T. 3 , Paquet T. 4 , Bouillaud E. 4 , Urva S. 3 , Anak O. 4 , Sellami D. 3 , Kobalava Z. 5
Conference proceedings
EUROPEAN JOURNAL OF CANCER
Publisher
ELSEVIER SCI LTD
Language
English
State
Published
DOI
10.1016/S0959-8049(11)71871-8
Volume
47
Year
2011
Organizations
  • 1 Klin JW Goethe Univ, Dept Med, Frankfurt 117548, Germany
  • 2 Natl Univ Singapore, Inst Canc, Singapore, Singapore
  • 3 Novartis Pharmaceut, NIA, Florham Pk, NJ USA
  • 4 Novartis Pharma AG, NIA, Basel, Switzerland
  • 5 Peoples Friendship Univ Russia, Ctr Appl Clin Pharmacol, Moscow, Russia
Cite
ГОСТ MLA RIS BibTex
Share

Other records